<document>

<filing_date>
2020-02-13
</filing_date>

<publication_date>
2020-08-20
</publication_date>

<priority_date>
2019-02-14
</priority_date>

<ipc_classes>
G16B20/00,G16B30/00,G16B40/00,G16H50/30
</ipc_classes>

<assignee>
MIRVIE
</assignee>

<inventors>
JAIN, MANEESH
NAMSARAEV, EUGENI
RASMUSSEN, MORTEN
REDDY, MITSU
SIDDIQUI, FAROOQ
SOLER, JOAN CAMUNAS
</inventors>

<docdb_family_id>
72044275
</docdb_family_id>

<title>
METHODS AND SYSTEMS FOR DETERMINING A PREGNANCY-RELATED STATE OF A SUBJECT
</title>

<abstract>
The present disclosure provides methods and systems directed to cell-free identification and/or monitoring of pregnancy-related states. A method for identifying or monitoring a presence or susceptibility of a pregnancy-related state of a subject may comprise assaying a cell-free biological sample derived from said subject to detect a set of biomarkers, and analyzing the set of biomarkers with a trained algorithm to determine the presence or susceptibility of the pregnancy-related state.
</abstract>

<claims>
WHAT IS CLAIMED IS:
1. A method for identifying a presence or susceptibility of a pregnancy-related state of a subject, comprising assaying transcripts or metabolites in a cell-free biological sample derived from said subject to detect a set of biomarkers, and analyzing said set of biomarkers with a trained algorithm to determine said presence or susceptibility of said pregnancy-related state.
2. The method of claim 1, further comprising assaying said transcripts in said cell-free biological sample derived from said subject to detect said set of biomarkers.
3. The method of claim 2, wherein said transcripts are assayed with nucleic acid
sequencing.
4. The method of claim 1, further comprising assaying said metabolites in said cell-free biological sample derived from said subject to detect said set of biomarkers.
5. The method of claim 4, wherein said metabolites are assayed with a metabolomics assay.
6. A method for identifying a presence or susceptibility of a pregnancy-related state of a subject, further comprising assaying a cell-free biological sample derived from said subject to detect a set of biomarkers, and analyzing said set of biomarkers with a trained algorithm to determine said presence or susceptibility of said pregnancy-related state among a set of at least three distinct pregnancy-related states at an accuracy of at least about 80%.
7. The method of any one of claims 1-6, wherein said pregnancy -related state is selected from the group consisting of pre-term birth, full-term birth, gestational age, due date, onset of labor, a pregnancy-related hypertensive disorder, eclampsia, gestational diabetes, a congenital disorder of a fetus of said subject, ectopic pregnancy, spontaneous abortion, stillbirth, a post partum complication, hyperemesis gravidarum, hemorrhage or excessive bleeding during delivery, premature rupture of membrane, premature rupture of membrane in pre-term birth, placenta previa, intrauterine/fetal growth restriction, macrosomia, a neonatal condition, and a fetal development stage or state.
8. The method of claim 6, wherein said pregnancy-related state is a sub-type of pre-term birth, and wherein said at least three distinct pregnancy-related states include at least two distinct sub-types of pre-term birth.
9. The method of claim 8, wherein said sub-type of pre-term birth is a molecular sub-type of pre-term birth, and wherein said at least two distinct sub-types of pre-term birth include at least two distinct molecular sub-types of pre-term birth.
10. The method of claim 9, wherein said molecular subtype of pre-term birth is selected from the group consisting of history of prior pre-term birth, spontaneous pre-term birth, ethnicity specific pre-term birth risk, and pre-term premature rupture of membrane (PPROM).
11. The method of claim 6, further comprising identifying a clinical intervention for said subject based at least in part on said presence or susceptibility of said pregnancy-related state.
12. The method of claim 9, wherein said clinical intervention is selected from a plurality of clinical interventions.
13. The method of claim 6, wherein said set of biomarkers comprises a genomic locus associated with due date, wherein said genomic locus is selected from the group consisting of genes listed in Table 1 and Table 7.
14. The method of claim 6, wherein said set of biomarkers comprises a genomic locus associated with gestational age, wherein said genomic locus is selected from the group consisting of genes listed in Table 2.
15. The method of claim 6, wherein said set of biomarkers comprises a genomic locus associated with pre-term birth, wherein said genomic locus is selected from the group consisting of genes listed in Table 5, genes listed in Table 6, genes listed in Table 8, RAB27B, RGS18, CLCN3, B3GNT2, COL24A1, CXCL8, and PTGS2.
16. The method of any one of claims 13-15, wherein said set of biomarkers comprises at least 5 distinct genomic loci.
17. The method of any one of claims 13-15, wherein said set of biomarkers comprises at least 10 distinct genomic loci.
18. The method of any one of claims 13-15, wherein said set of biomarkers comprises at least 25 distinct genomic loci.
19. The method of any one of claims 13-15, wherein said set of biomarkers comprises at least 50 distinct genomic loci.
20. The method of any one of claims 13-15, wherein said set of biomarkers comprises at least 100 distinct genomic loci.
21. The method of any one of claims 13-15, wherein said set of biomarkers comprises at least 150 distinct genomic loci.
22. A method for identifying or monitoring a presence or susceptibility of a pregnancyrelated state of a subject, comprising:
(a) using a first assay to process a cell-free biological sample derived from said subject to generate a first dataset;
(b) using a second assay to process a vaginal or cervical biological sample derived from said subject to generate a second dataset comprising a microbiome profile of said vaginal or cervical biological sample;
(c) using a trained algorithm to process at least said first dataset and said second dataset to determine said presence or susceptibility of said pregnancy-related state, which trained algorithm has an accuracy of at least about 80% over at least 50 independent samples; and
(d) electronically outputting a report indicative of said presence or susceptibility of said pregnancy -related state of said subject.
23. The method of claim 22, wherein said first assay comprises using cell-free ribonucleic acid (cfRNA) molecules derived from said cell-free biological sample to generate transcriptomic data, using cell-free deoxyribonucleic acid (cfDNA) molecules derived from said cell-free biological sample to generate genomic data, using proteins derived from said first cell-free biological sample to generate proteomic data, or using metabolites derived from said first cellfree biological sample to generate metabolomic data.
24. The method of claim 22, wherein said cell-free biological sample is from a blood of said subject.
25. The method of claim 22, wherein said cell-free biological sample is from a urine of said subject.
26. The method of claim 22, wherein said first dataset comprises a first set of biomarkers associated with said pregnancy-related state.
27. The method of claim 26, wherein said second dataset comprises a second set of biomarkers associated with said pregnancy-related state.
28. The method of claim 27, wherein said second set of biomarkers is different from said first set of biomarkers.
29. The method of claim 22, wherein said pregnancy-related state is selected from the group consisting of pre-term birth, full-term birth, gestational age, due date, onset of labor, a pregnancy-related hypertensive disorder, eclampsia, gestational diabetes, a congenital disorder of a fetus of the subject, ectopic pregnancy, spontaneous abortion, stillbirth, a post-partum complication, hyperemesis gravidarum, hemorrhage or excessive bleeding during delivery, premature rupture of membrane, premature rupture of membrane in pre-term birth, placenta previa, intrauterine/fetal growth restriction, macrosomia, a neonatal condition, and a fetal development stage or state.
30. The method of claim 29, wherein said pregnancy-related state comprises pre-term birth.
31. The method of claim 29, wherein said pregnancy-related state comprises gestational age.
32. The method of claim 22, wherein said cell-free biological sample is selected from the group consisting of cell-free ribonucleic acid (cfRNA), cell-free deoxyribonucleic acid
(cfDNA), cell-free fetal DNA (cffDNA), plasma, serum, urine, saliva, amniotic fluid, and derivatives thereof.
33. The method of claim 22, wherein said cell-free biological sample is obtained or derived from said subject using an ethyl enediaminetetraacetic acid (EDTA) collection tube, a cell-free RNA collection tube, or a cell-free deoxyribonucleic acid (DNA) collection tube.
34. The method of claim 22, further comprising fractionating a whole blood sample of said subject to obtain said cell-free biological sample.
35. The method of claim 22, wherein said first assay comprises a cell-free ribonucleic acid (cfRNA) assay or a metabolomics assay.
36. The method of claim 35, wherein said metabolomics assay comprises targeted mass spectroscopy (MS) or an immune assay.
37. The method of claim 22, wherein said cell-free biological sample comprises cell-free ribonucleic acid (cfRNA) or urine.
38. The method of claim 22, wherein said first assay or said second assay comprises quantitative polymerase chain reaction (qPCR).
39. The method of claim 22, wherein said first assay or said second assay comprises a home use test configured to be performed in a home setting.
40. The method of claim 22, wherein said trained algorithm determines said presence or susceptibility of said pregnancy-related state of said subject at a sensitivity of at least about 80%.
41. The method of claim 22, wherein said trained algorithm determines said presence or susceptibility of said pregnancy-related state of said subject at a sensitivity of at least about 90%.
42. The method of claim 22, wherein said trained algorithm determines said presence or susceptibility of said pregnancy-related state of said subject at a sensitivity of at least about 95%.
43. The method of claim 22, wherein said trained algorithm determines said presence or susceptibility of said pregnancy-related state of said subject at a positive predictive value (PPV) of at least about 70%.
44. The method of claim 22, wherein said trained algorithm determines said presence or susceptibility of said pregnancy-related state of said subject at a positive predictive value (PPV) of at least about 80%.
45. The method of claim 22, wherein said trained algorithm determines said presence or susceptibility of said pregnancy-related state of said subject at a positive predictive value (PPV) of at least about 90%.
46. The method of claim 22, wherein said trained algorithm determines said presence or susceptibility of said pregnancy-related state of said subject with an Area Under Curve (AUC) of at least about 0.90.
47. The method of claim 22, wherein said trained algorithm determines said presence or susceptibility of said pregnancy-related state of said subject with an Area Under Curve (AUC) of at least about 0.95.
48. The method of claim 22, wherein said trained algorithm determines said presence or susceptibility of said pregnancy-related state of said subject with an Area Under Curve (AUC) of at least about 0.99.
49. The method of claim 22, wherein said subject is asymptomatic for one or more of: pre term birth, onset of labor, a pregnancy-related hypertensive disorder, eclampsia, gestational diabetes, a congenital disorder of a fetus of the subject, ectopic pregnancy, spontaneous abortion, stillbirth, a post-partum complication, hyperemesis gravidarum, hemorrhage or excessive bleeding during delivery, premature rupture of membrane, premature rupture of membrane in pre-term birth, placenta previa, intrauterine/fetal growth restriction, macrosomia, a neonatal condition, and an abnormal fetal development stage or state.
50. The method of claim 22, wherein said trained algorithm is trained using at least about 10 independent training samples associated with said presence or susceptibility of said pregnancyrelated state.
51. The method of claim 22, wherein said trained algorithm is trained using no more than about 100 independent training samples associated with said presence or susceptibility of said pregnancy-related state.
52. The method of claim 22, wherein said trained algorithm is trained using a first set of independent training samples associated with a presence or susceptibility of said pregnancyrelated state and a second set of independent training samples associated with an absence or no susceptibility of said pregnancy-related state.
53. The method of claim 22, wherein (c) comprises using said trained algorithm or another trained algorithm to process a set of clinical health data of said subject to determine said presence or susceptibility of said pregnancy-related state.
54. The method of claim 22, wherein (a) comprises (i) subjecting said cell-free biological sample to conditions that are sufficient to isolate, enrich, or extract a set of ribonucleic (RNA) molecules, deoxyribonucleic acid (DNA) molecules, proteins, or metabolites, and (ii) analyzing said set of RNA molecules, DNA molecules, proteins, or metabolites using said first assay to generate said first dataset.
55. The method of claim 54, further comprising extracting a set of nucleic acid molecules from said cell-free biological sample, and subjecting said set of nucleic acid molecules to sequencing to generate a set of sequencing reads, wherein said first dataset comprises said set of sequencing reads.
56. The method of claim 22, wherein (b) comprises (i) subjecting said vaginal or cervical biological sample to conditions that are sufficient to isolate, enrich, or extract a population of microbes, and (ii) analyzing said population of microbes using said second assay to generate said second dataset.
57. The method of claim 55, wherein said sequencing is massively parallel sequencing.
58. The method of claim 55, wherein said sequencing comprises nucleic acid amplification.
59. The method of claim 58, wherein said nucleic acid amplification comprises polymerase chain reaction (PCR).
60. The method of claim 59, wherein said sequencing comprises use of substantially simultaneous reverse transcription (RT) and polymerase chain reaction (PCR).
61. The method of claim 55, further comprising using probes configured to selectively enrich said set of nucleic acid molecules corresponding to a panel of one or more genomic loci.
62. The method of claim 61, wherein said probes are nucleic acid primers.
63. The method of claim 61, wherein said probes have sequence complementarity with nucleic acid sequences of said panel of said one or more genomic loci.
64. The method of claim 61, wherein said panel of said one or more genomic loci comprises at least one genomic locus selected from the group consisting of ACTB, ADAM12, ALPP, ANXA3, APLF, ARG1, AVPR1A, CAMP, CAPN6, CD180, CGA, CGB, CLCN3,CPVL,
CSH1, CSH2, CSHL1, CYP3A7, DAPPl, DCX, DEFA4, DGCR14, ELANE, ENAH, EPB42, FABP1, FAM212B-AS1, FGA, FGB, FRMD4B, FRZB, FSTL3, GH2, GNAZ, HAL,
HSD17B1, HSD3B1, HSPB8, Immune, ITIH2, KLF9, KNG1, KRT8, LGALS14, LTF,
LYPLAL1, MAP3K7CL, MEF2C, MMD, MMP8, MOB IB, NFATC2, OTC, P2RY12, PAPPA, PGLYRP1, PKHD1L1, PKHD1L1, PLAC1, PLAC4, POLE2, PPBP, PSG1, PSG4, PSG7, PTGER3, RABl lA, RAB27B, RAP 1 GAP, RGS18, RPL23AP7, S100A8, S100A9, SI OOP, SERPINA7, SLC2A2, SLC38A4, SLC4A1, TBC1D15, VCAN, VGLL1, B3GNT2, COL24A1, CXCL8, and PTGS2.
65. The method of claim 61, wherein said panel of said one or more genomic loci comprises at least 5 distinct genomic loci.
66. The method of claim 61, wherein said panel of said one or more genomic loci comprises at least 10 distinct genomic loci.
67. The method of claim 61, wherein said panel of said one or more genomic loci comprises a genomic locus associated with pre-term birth, wherein said genomic locus is selected from the group consisting of ADAM 12, ANXA3, APLF, AVPR1A, CAMP, CAPN6, CD180, CGA,
CGB, CLCN3,CPVL, CSH2, CSHL1, CYP3A7, DAPPl, DGCR14, ELANE, ENAH,
FAM212B-AS1, FRMD4B, GH2, HSPB8, Immune, KLF9, KRT8, LGALS14, LTF, LYPLAL1, MAP3K7CL, MMD, MOB IB, NFATC2, P2RY12, PAPPA, PGLYRPl, PKHDILI, PKHD1L1, PLAC1, PLAC4, POLE2, PPBP, PSG1, PSG4, PSG7, RABl lA, RAB27B, RAP 1 GAP, RGS18, RPL23AP7, TBC1D15, VCAN, VGLL1, B3GNT2, COL24A1, CXCL8, and PTGS2.
68. The method of claim 61, wherein said panel of said one or more genomic loci comprises a genomic locus associated with gestational age, wherein said genomic locus is selected from the group consisting of ACTB, ADAM 12, ALPP, ANXA3, ARGl, CAMP, CAPN6, CGA, CGB, CSH1, CSH2, CSHLl, CYP3A7, DCX, DEFA4, EPB42, FABP1, FGA, FGB, FRZB, FSTL3, GH2, GNAZ, HAL, HSD17B1, HSD3B1, HSPB8, ITIH2, KNG1, LGALS14, LTF, MEF2C, MMP8, OTC, PAPPA, PGLYRPl, PLAC1, PLAC4, PSG1, PSG4, PSG7, PTGER3, S100A8, S100A9, S100P, SERPINA7, SLC2A2, SLC38A4, SLC4A1, VGLL1, RAB27B, RGS18, CLCN3, B3GNT2, COL24A1, CXCL8, and PTGS2.
69. The method of claim 61, wherein said panel of said one or more genomic loci comprises a genomic locus associated with due date, wherein said genomic locus is selected from the group consisting of genes listed in Table 1 and Table 7.
70. The method of claim 61, wherein said panel of said one or more genomic loci comprises a genomic locus associated with gestational age, wherein said genomic locus is selected from the group consisting of genes listed in Table 2.
71. The method of claim 61, wherein said panel of said one or more genomic loci comprises a genomic locus associated with pre-term birth, wherein said genomic locus is selected from the group of genes listed in Table 5, genes listed in Table 6, genes listed in Table 8, RAB27B, RGS18, CLCN3, B3GNT2, COL24A1, CXCL8, and PTGS2.
72. The method of any one of claims 69-71, wherein said panel of said one or more genomic loci comprises at least 5 distinct genomic loci.
73. The method of any one of claims 69-71, wherein said panel of said one or more genomic loci comprises at least 10 distinct genomic loci.
74. The method of any one of claims 69-71, wherein said panel of said one or more genomic loci comprises at least 25 distinct genomic loci.
75. The method of any one of claims 69-71, wherein said panel of said one or more genomic loci comprises at least 50 distinct genomic loci.
76. The method of any one of claims 69-71, wherein said panel of said one or more genomic loci comprises at least 100 distinct genomic loci.
77. The method of any one of claims 69-71, wherein said panel of said one or more genomic loci comprises at least 150 distinct genomic loci.
78. The method of claim 22, wherein said cell-free biological sample is processed without nucleic acid isolation, enrichment, or extraction.
79. The method of claim 22, wherein said report is presented on a graphical user interface of an electronic device of a user.
80. The method of claim 79, wherein said user is said subject.
81. The method of claim 22, further comprising determining a likelihood of said
determination of said presence or susceptibility of said pregnancy-related state of said subject.
82. The method of claim 22, wherein said trained algorithm comprises a supervised machine learning algorithm.
83. The method of claim 82, wherein said supervised machine learning algorithm comprises a deep learning algorithm, a support vector machine (SVM), a neural network, or a Random Forest.
84. The method of claim 22, further comprising providing said subject with a therapeutic intervention for said presence or susceptibility of said pregnancy-related state.
85. The method of claim 84, wherein said therapeutic intervention comprises hydroxyprogesterone caproate, a vaginal progesterone, a natural progesterone IVR product, an prostaglandin F2 alpha receptor antagonist, or a beta2-adrenergic receptor agonist.
86. The method of claim 22, further comprising monitoring said presence or susceptibility of said pregnancy-related state, wherein said monitoring comprises assessing said presence or susceptibility of said pregnancy-related state of said subject at a plurality of time points, wherein said assessing is based at least on said presence or susceptibility of said pregnancy-related state determined in (d) at each of said plurality of time points.
87. The method of claim 86, wherein a difference in said assessment of said presence or susceptibility of said pregnancy-related state of said subject among said plurality of time points is indicative of one or more clinical indications selected from the group consisting of: (i) a diagnosis of said presence or susceptibility of said pregnancy-related state of said subject, (ii) a prognosis of said presence or susceptibility of said pregnancy-related state of said subject, and (iii) an efficacy or non-efficacy of a course of treatment for treating said presence or
susceptibility of said pregnancy-related state of said subject.
88. The method of claim 30, further comprising stratifying said pre-term birth by using said trained algorithm to determine a molecular sub-type of said pre-term birth from among a plurality of distinct molecular subtypes of pre-term birth.
89. The method of claim 88, wherein said plurality of distinct molecular subtypes of pre term birth comprises a molecular subtype of pre-term birth selected from the group consisting of history of prior pre-term birth, spontaneous pre-term birth, ethnicity specific pre-term birth risk, and pre-term premature rupture of membrane (PPROM).
90. A computer-implemented method for predicting a risk of pre-term birth of a subject, comprising:
(a) receiving clinical health data of said subject, wherein said clinical health data
comprises a plurality of quantitative or categorical measures of said subject;
(b) using a trained algorithm to process said clinical health data of said subject to
determine a risk score indicative of said risk of pre-term birth of said subject; and
(c) electronically outputting a report indicative of said risk score indicative of said risk of pre-term birth of said subject.
91. The method of claim 90, wherein said clinical health data comprises one or more quantitative measures selected from the group consisting of age, weight, height, body mass index (BMI), blood pressure, heart rate, glucose levels, number of previous pregnancies, and number of previous births.
-HO-
92. The method of claim 90, wherein said clinical health data comprises one or more categorical measures selected from the group consisting of race, ethnicity, history of medication or other clinical treatment, history of tobacco use, history of alcohol consumption, daily activity or fitness level, genetic test results, blood test results, imaging results, and fetal screening results.
93. The method of claim 90, wherein said trained algorithm determines said risk of pre-term birth of said subject at a sensitivity of at least about 80%.
94. The method of claim 90, wherein said trained algorithm determines said risk of pre-term birth of said subject at a specificity of at least about 80%.
95. The method of claim 90, wherein said trained algorithm determines said risk of pre-term birth of said subject at a positive predictive value (PPV) of at least about 80%.
96. The method of claim 90, wherein said trained algorithm determines said risk of pre-term birth of said subject at a negative predictive value (NPV) of at least about 80%.
97. The method of claim 90, wherein said trained algorithm determines said risk of pre-term birth of said subject with an Area Under Curve (AUC) of at least about 0.9.
98. The method of claim 90, wherein said subject is asymptomatic for one or more of: pre term birth, onset of labor, a pregnancy-related hypertensive disorder, eclampsia, gestational diabetes, a congenital disorder of a fetus of said subject, ectopic pregnancy, spontaneous abortion, stillbirth, a post-partum complication, hyperemesis gravidarum, hemorrhage or excessive bleeding during delivery, premature rupture of membrane, premature rupture of membrane in pre-term birth, placenta previa, intrauterine/fetal growth restriction, macrosomia, a neonatal condition, and an abnormal fetal development stage or state.
99. The method of claim 90, wherein said trained algorithm is trained using at least about 10 independent training samples associated with pre-term birth.
100. The method of claim 90, wherein said trained algorithm is trained using no more than about 100 independent training samples associated with pre-term birth.
101. The method of claim 90, wherein said trained algorithm is trained using a first set of independent training samples associated with a presence of pre-term birth and a second set of independent training samples associated with an absence of pre-term birth.
102. The method of claim 90, wherein said report is presented on a graphical user interface of an electronic device of a user.
103. The method of claim 102, wherein said user is said subject.
104. The method of claim 90, wherein said trained algorithm comprises a supervised machine learning algorithm.
105. The method of claim 104, wherein said supervised machine learning algorithm comprises a deep learning algorithm, a support vector machine (SVM), a neural network, or a Random Forest.
106. The method of claim 90, further comprising providing said subject with a therapeutic intervention based at least in part on said risk score indicative of said risk of pre-term birth.
107. The method of claim 106, wherein said therapeutic intervention comprises
hydroxyprogesterone caproate, a vaginal progesterone, a natural progesterone IVR product, an prostaglandin F2 alpha receptor antagonist, or a beta2-adrenergic receptor agonist.
108. The method of claim 90, further comprising monitoring said risk of pre-term birth, wherein said monitoring comprises assessing said risk of pre-term birth of said subject at a plurality of time points, wherein said assessing is based at least on said risk score indicative of said risk of pre-term birth determined in (b) at each of said plurality of time points.
109. The method of claim 90, further comprising refining said risk score indicative of said risk of pre-term birth of said subject by performing one or more subsequent clinical tests for said subject, and processing results from said one or more subsequent clinical tests using a trained algorithm to determine an updated risk score indicative of said risk of pre-term birth of said subject.
110. The method of claim 109, wherein said one or more subsequent clinical tests comprise an ultrasound imaging or a blood test.
111. The method of claim 90, wherein said risk score comprises a likelihood of said subject having a pre-term birth within a pre-determined duration of time.
112. The method of claim 111, wherein said pre-determined duration of time is at least about 1 hour.
113. A computer system for predicting a risk of pre-term birth of a subject, comprising:
a database that is configured to store clinical health data of said subject, wherein said clinical health data comprises a plurality of quantitative or categorical measures of said subject; and
one or more computer processors operatively coupled to said database, wherein said one or more computer processors are individually collectively programmed to:
(i) use a trained algorithm to process said clinical health data of said subject to
determine a risk score indicative of said risk of pre-term birth of said subject; and
(ii) electronically output a report indicative of said risk score indicative of said risk of pre-term birth of said subject.
114. The computer system of claim 113, further comprising an electronic display operatively coupled to said one or more computer processors, wherein said electronic display comprises a graphical user interface that is configured to display said report.
115. A non-transitory computer readable medium comprising machine-executable code that, upon execution by one or more computer processors, implements a method for predicting a risk of pre-term birth of a subject, said method comprising:
(a) receiving clinical health data of said subject, wherein said clinical health data
comprises a plurality of quantitative or categorical measures of said subject;
(b) using a trained algorithm to process said clinical health data of said subject to
determine a risk score indicative of said risk of pre-term birth of said subject; and
(c) electronically outputting a report indicative of said risk score indicative of said risk of pre-term birth of said subject.
116. A method for determining a due date, due date range, or gestational age of a fetus of a pregnant subject, comprising assaying a cell-free biological sample derived from said pregnant subject to detect a set of biomarkers, and analyzing said set of biomarkers with a trained algorithm to determine said due date, due date range, or gestational age of said fetus.
117. The method of claim 116, further comprising analyzing an estimated due date or due date range of said fetus of said pregnant subject using said trained algorithm, wherein said estimated due date or due date range is generated from ultrasound measurements of said fetus.
118. The method of claim 116 or 117, wherein said set of biomarkers comprises a genomic locus associated with due date, wherein said genomic locus is selected from the group of genes listed in Table 1 and Table 7.
119. The method of claim 118, wherein said set of biomarkers comprises at least 5 distinct genomic loci.
120. The method of claim 118, wherein said set of biomarkers comprises at least 10 distinct genomic loci.
121. The method of claim 118, wherein said set of biomarkers comprises at least 25 distinct genomic loci.
122. The method of claim 118, wherein said set of biomarkers comprises at least 50 distinct genomic loci.
123. The method of claim 118, wherein said set of biomarkers comprises at least 100 distinct genomic loci.
124. The method of claim 118, wherein said set of biomarkers comprises at least 150 distinct genomic loci.
125. The method of any one of claims 116-124, further comprising identifying a clinical intervention for said pregnant subject based at least in part on said determined due date.
126. The method of claim 125, wherein said clinical intervention is selected from a plurality of clinical interventions.
127. The method of claim 116, wherein said time-to-delivery is less than 7.5 weeks.
128. The method of claim 127, wherein said genomic locus is selected from ACKR2,
AKAP3, AN05, Clorf 21, C2orf 42, CARNS1, CASC15, CCDC102B, CDC45, CDIPT, CMTM1, COPS8, CTD-2267D19.3, CTD-2349P21.9, CXorf 65, DDX11L1, DGUOK,
DPAGT1, EIF4A1P2, FANKl, FERMT1, FKRP, GAMT, GOLGA6L4, KLLN, LINC01347, LTA, MAPK12, METRN, MKRN4P, MPC2, MYL12BP1, NME4, NPM1P30, PCLO, PIF1, PTP4A3, RIMKLB, RP13-88F20.1, S100B, SIGLEC14, SLAIN1, SPAT A33, TFAP2C, TMSB4XP8, TRGV10, and ZNF124.
129. The method of claim 116, wherein said time-to-delivery is less than 5 weeks.
130. The method of claim 129, wherein said genomic locus is selected from C2orf 68, CACNB3, CD40, CDKL5, CTBS, CTD-2272G21.2, CXCL8, DHRS7B, EIF5A2, IFITM3, MTR24-2, MTSS 1, MYSM1, NCK1-AS1, NR1H4, PDE1C, PEMT, PEX7, PIF1, PPP2R3A, RABIF, SIGLEC14, SLC25A53, SPANXN4, SUPT3H, ZC2HC1C, ZMYM1, and ZNF124.
131. The method of claim 117, wherein said time-to-delivery is less than 7.5 weeks.
132. The method of claim 131, wherein said genomic locus is selected from ACKR2,
AKAP3, AN05, Clorf 21, C2orf 42, CARNS1, CASC15, CCDC102B, CDC45, CDIPT, CMTM1, collectionga, COPS8, CTD-2267D19.3, CTD-2349P21.9, DDX11L1, DGUOK, DPAGT1, EIF4A1P2, FANK1, FERMT1, FKRP, GAMT, GOLGA6L4, KLLN, LINC01347, LTA, MAPK12, METRN, MPC2, MYL12BP1, NME4, NPM1P30, PCLO, PIF1, PTP4A3, RIMKLB, RP13-88F20.1, S100B, SIGLEC14, SLAIN1, SPAT A33, STAT1, TFAP2C,
TMEM94, TMSB4XP8, TRGV10, ZNF124, and ZNF713.
133. The method of claim 116, wherein said time-to-delivery is less than 5 weeks.
134. The method of claim 133, wherein said genomic locus is selected from ATP6V1E1P1, ATP8A2, C2orf 68, CACNB3, CD40, CDKL4, CDKL5, CEP152, CLEC4D, COL18A1, collectionga, COX16, CTBS, CTD-2272G21.2, CXCL2, CXCL8, DHRS7B, DPPA4, EIF5A2, FERMTl, GNB1L, IFITM3, KATNALl, LRCH4, MBD6, MIR24-2, MTSS1, MYSM1, NCK1- AS1, NPIPB4, NR1H4, PDE1C, PEMT, PEX7, PIF1, PPP2R3A, PXDN, RABIF, SERTAD3, SIGLEC14, SLC25A53, SPANXN4, SSH3, SUPT3H, TMEM150C, TNFAIP6, UPP1, XKR8, ZC2HC1C, ZMYM1, and ZNF124.
135. The method of claim 116, wherein said trained algorithm comprises a linear regression model or an ANOVA model.
136. The method of claim 135, wherein said ANOVA model determines a maximumlikelihood time window corresponding to said due date from among a plurality of time windows.
137. The method of claim 136, wherein said maximum-likelihood time window corresponds to a time-to-delivery of at least 1 week.
138. The method of claim 135, wherein said ANOVA model determines a probability or likelihood of a time window corresponding to said due date from among a plurality of time windows.
139. The method of claim 137, wherein said ANOVA model calculates a probabilityweighted average across said plurality of time windows to determine an average or expected time window distance.
140. A method for detecting a presence or risk of a prenatal metabolic genetic disease of a fetus of a pregnant subject, comprising:
assaying ribonucleic acid (RNA) in a cell-free biological sample derived from said pregnant subject to detect a set of biomarkers, and
analyzing said set of biomarkers with a trained algorithm to detect said presence or risk of said prenatal metabolic genetic disease.
141. A method for detecting at least two health or physiological conditions of a fetus of a pregnant subject or of said pregnant subject, comprising:
assaying a first cell-free biological sample obtained or derived from said pregnant subject at a first time point and a second cell-free biological sample obtained or derived from said pregnant subject at a second time point, to detect a first set of biomarkers at said first time point and a second set of biomarkers at said second time point, and
analyzing said first set of biomarkers or said second set of biomarkers with a trained algorithm to detect said at least two health or physiological conditions.
142. The method of claim 141, wherein said at least two health or physiological conditions are selected from the group consisting of pre-term birth, full-term birth, gestational age, due date, onset of labor, a pregnancy-related hypertensive disorder, eclampsia, gestational diabetes, a congenital disorder of a fetus of said subject, ectopic pregnancy, spontaneous abortion, stillbirth, a post-partum complication, hyperemesis gravidarum, hemorrhage or excessive bleeding during delivery, premature rupture of membrane, premature rupture of membrane in pre-term birth, placenta previa, intrauterine/fetal growth restriction, macrosomia, a neonatal condition, and a fetal development stage or state.
143. The method of claim 141, wherein said set of biomarkers comprises a genomic locus associated with due date, wherein said genomic locus is selected from the group consisting of genes listed in Table 1 and Table 7.
144. The method of claim 141, wherein said set of biomarkers comprises a genomic locus associated with gestational age, wherein said genomic locus is selected from the group consisting of genes listed in Table 2.
145. The method of claim 141, wherein said set of biomarkers comprises a genomic locus associated with pre-term birth, wherein said genomic locus is selected from the group consisting of genes listed in Table 5, genes listed in Table 6, genes listed in Table 8, RAB27B, RGS18, CLCN3, B3GNT2, COL24A1, CXCL8, and PTGS2.
146. The method of claim 141, wherein said set of biomarkers comprises at least 5 distinct genomic loci.
147. A method comprising:
assaying one or more cell-free biological samples obtained or derived from a pregnant subject to detect a set of biomarkers; and
analyzing said set of biomarkers to identify (1) a due date or a range thereof of a fetus of said pregnant subject and (2) a health or physiological condition of said fetus of said pregnant subject or of said pregnant subject.
148. The method of claim 147, further comprising analyzing said set of biomarkers with a trained algorithm.
149. The method of claim 147, wherein said health or physiological condition is selected from the group consisting of pre-term birth, full-term birth, gestational age, due date, onset of labor, a pregnancy-related hypertensive disorder, eclampsia, gestational diabetes, a congenital disorder of a fetus of said subject, ectopic pregnancy, spontaneous abortion, stillbirth, a post-partum complication, hyperemesis gravidarum, hemorrhage or excessive bleeding during delivery, premature rupture of membrane, premature rupture of membrane in pre-term birth, placenta previa, intrauterine/fetal growth restriction, macrosomia, a neonatal condition, and a fetal development stage or state.
150. The method of claim 147, wherein said set of biomarkers comprises a genomic locus associated with due date, wherein said genomic locus is selected from the group consisting of genes listed in Table 1 and Table 7.
151. The method of claim 147, wherein said set of biomarkers comprises a genomic locus associated with gestational age, wherein said genomic locus is selected from the group consisting of genes listed in Table 2.
152. The method of claim 147, wherein said set of biomarkers comprises a genomic locus associated with pre-term birth, wherein said genomic locus is selected from the group consisting of genes listed in Table 5, genes listed in Table 6, genes listed in Table 8, RAB27B, RGS18, CLCN3, B3GNT2, COL24A1, CXCL8, and PTGS2.
153. The method of claim 147, wherein said set of biomarkers comprises at least 5 distinct genomic loci.
</claims>
</document>
